Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel +18 more
wiley +1 more source
Incidence, pathogenesis, clinical manifestations, and pharmacological management of the 2026 Andes virus outbreak. [PDF]
Ghasemiyeh P, Mohammadi-Samani S.
europepmc +1 more source
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi +1 more
wiley +1 more source
A Cell-Penetrating Peptide and Signal Sequence Fusion DNA Vaccine Enhances CD8+ T Cell-Mediated Anti-Tumor Immunity Targeting HPV-16 Cervical Cancer Antigens. [PDF]
Chang YC +6 more
europepmc +1 more source
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva +8 more
wiley +1 more source
Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications. [PDF]
Pirogovsky KM, Hawiger D.
europepmc +1 more source
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis +4 more
wiley +1 more source
Developing neoantigen cancer vaccines: where are we now? [PDF]
Markosyan N, Vonderheide RH.
europepmc +1 more source
What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady +6 more
wiley +1 more source
Comparative Efficacy of Intramuscular and Intradermal Porcilis Lawsonia<sup>®</sup> Administration Under a Laboratory Challenge Model and Korean Field Conditions. [PDF]
Lee S +7 more
europepmc +1 more source

